Researchers have uncovered an early survival response in ovarian cancer cells that may limit the effectiveness of widely used ...
PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show high potency across ...
HRD-positive tumors derived the largest median PFS gain with rucaparib maintenance versus placebo, consistent with PARP ...
Scientists have uncovered a hidden reason why cancer treatments don’t work equally well for everyone. Certain drugs can ...
PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers. Niraparib approved for all-comers whose ...
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients ...
Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive ...
In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...
Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...
The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance. A new analysis using CRISPR screens has revealed insights that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results